TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:TEVA • US8816242098

34.69 USD
-0.11 (-0.32%)
At close: Feb 6, 2026
34.91 USD
+0.22 (+0.63%)
After Hours: 2/6/2026, 8:08:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

TEVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. TEVA has an excellent profitability rating, but there are concerns on its financial health. TEVA may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year TEVA was profitable.
  • In the past year TEVA had a positive cash flow from operations.
  • In multiple years TEVA reported negative net income over the last 5 years.
  • In the past 5 years TEVA always reported a positive cash flow from operatings.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B -15B

1.2 Ratios

  • With an excellent Return On Assets value of 3.46%, TEVA belongs to the best of the industry, outperforming 83.25% of the companies in the same industry.
  • TEVA's Return On Equity of 17.81% is amongst the best of the industry. TEVA outperforms 89.53% of its industry peers.
  • The Return On Invested Capital of TEVA (9.93%) is better than 89.53% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for TEVA is below the industry average of 12.65%.
  • The 3 year average ROIC (9.79%) for TEVA is below the current ROIC(9.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROIC 9.93%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)9.79%
ROIC(5y)8.89%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • TEVA's Profit Margin of 8.16% is amongst the best of the industry. TEVA outperforms 83.25% of its industry peers.
  • With an excellent Operating Margin value of 19.87%, TEVA belongs to the best of the industry, outperforming 87.43% of the companies in the same industry.
  • TEVA's Operating Margin has been stable in the last couple of years.
  • With a decent Gross Margin value of 52.89%, TEVA is doing good in the industry, outperforming 65.44% of the companies in the same industry.
  • In the last couple of years the Gross Margin of TEVA has grown nicely.
Industry RankSector Rank
OM 19.87%
PM (TTM) 8.16%
GM 52.89%
OM growth 3Y-2.92%
OM growth 5Y0.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TEVA is still creating some value.
  • The number of shares outstanding for TEVA has been increased compared to 1 year ago.
  • The number of shares outstanding for TEVA has been increased compared to 5 years ago.
  • Compared to 1 year ago, TEVA has an improved debt to assets ratio.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • The Debt to FCF ratio of TEVA is 14.64, which is on the high side as it means it would take TEVA, 14.64 years of fcf income to pay off all of its debts.
  • TEVA has a better Debt to FCF ratio (14.64) than 76.96% of its industry peers.
  • A Debt/Equity ratio of 1.89 is on the high side and indicates that TEVA has dependencies on debt financing.
  • The Debt to Equity ratio of TEVA (1.89) is worse than 78.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF 14.64
Altman-Z N/A
ROIC/WACC1.22
WACC8.15%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • A Current Ratio of 1.04 indicates that TEVA should not have too much problems paying its short term obligations.
  • TEVA's Current ratio of 1.04 is on the low side compared to the rest of the industry. TEVA is outperformed by 84.29% of its industry peers.
  • TEVA has a Quick Ratio of 1.04. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of TEVA (0.80) is worse than 81.68% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.8
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • TEVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.27%, which is quite good.
  • TEVA shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.89% yearly.
  • TEVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
  • Measured over the past years, TEVA shows a small growth in Revenue. The Revenue has been growing by 0.71% on average per year.
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%

3.2 Future

  • TEVA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.67% yearly.
  • The Revenue is expected to grow by 1.00% on average over the next years.
EPS Next Y-4.58%
EPS Next 2Y3.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.34%
Revenue Next 2Y1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 11.60, the valuation of TEVA can be described as reasonable.
  • Based on the Price/Earnings ratio, TEVA is valued cheaply inside the industry as 89.01% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.93, TEVA is valued rather cheaply.
  • A Price/Forward Earnings ratio of 12.18 indicates a correct valuation of TEVA.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 86.39% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of TEVA to the average of the S&P500 Index (27.77), we can say TEVA is valued rather cheaply.
Industry RankSector Rank
PE 11.6
Fwd PE 12.18
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TEVA is valued cheaply inside the industry as 85.86% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, TEVA is valued cheaper than 80.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF 34.66
EV/EBITDA 11.97
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

  • TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.67%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TEVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (2/6/2026, 8:08:13 PM)

After market: 34.91 +0.22 (+0.63%)

34.69

-0.11 (-0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-28
Earnings (Next)05-05
Inst Owners14.54%
Inst Owner Change0.81%
Ins Owners0.42%
Ins Owner Change-1.67%
Market Cap39.79B
Revenue(TTM)17.26B
Net Income(TTM)1.41B
Analysts82.86
Price Target0.11 (-99.68%)
Short Float %2.94%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.53%
Min EPS beat(2)16.51%
Max EPS beat(2)38.54%
EPS beat(4)4
Avg EPS beat(4)16.39%
Min EPS beat(4)4.65%
Max EPS beat(4)38.54%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)9
Avg EPS beat(12)5.55%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)0.9%
Max Revenue beat(2)5.75%
Revenue beat(4)2
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)0.11%
Revenue beat(12)8
Avg Revenue beat(12)1.11%
Revenue beat(16)8
Avg Revenue beat(16)-0.59%
PT rev (1m)4.75%
PT rev (3m)98.2%
EPS NQ rev (1m)-7.96%
EPS NQ rev (3m)-4.24%
EPS NY rev (1m)1.21%
EPS NY rev (3m)2.6%
Revenue NQ rev (1m)-3.61%
Revenue NQ rev (3m)-2.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.1%
Valuation
Industry RankSector Rank
PE 11.6
Fwd PE 12.18
P/S 2.31
P/FCF 34.66
P/OCF 24.13
P/B 5.03
P/tB N/A
EV/EBITDA 11.97
EPS(TTM)2.99
EY8.62%
EPS(NY)2.85
Fwd EY8.21%
FCF(TTM)1
FCFY2.88%
OCF(TTM)1.44
OCFY4.14%
SpS15.04
BVpS6.9
TBVpS-10.35
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.54
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROCE 12.57%
ROIC 9.93%
ROICexc 11.42%
ROICexgc 68.51%
OM 19.87%
PM (TTM) 8.16%
GM 52.89%
FCFM 6.65%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)9.79%
ROIC(5y)8.89%
ROICexc(3y)11.13%
ROICexc(5y)9.93%
ROICexgc(3y)65.11%
ROICexgc(5y)55.38%
ROCE(3y)12.4%
ROCE(5y)11.26%
ROICexgc growth 3Y16.18%
ROICexgc growth 5Y11.01%
ROICexc growth 3Y9.88%
ROICexc growth 5Y9.93%
OM growth 3Y-2.92%
OM growth 5Y0.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF 14.64
Debt/EBITDA 3.38
Cap/Depr 50%
Cap/Sales 2.9%
Interest Coverage 250
Cash Conversion 37.21%
Profit Quality 81.48%
Current Ratio 1.04
Quick Ratio 0.8
Altman-Z N/A
F-Score8
WACC8.15%
ROIC/WACC1.22
Cap/Depr(3y)47.55%
Cap/Depr(5y)45.36%
Cap/Sales(3y)3.08%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
EPS Next Y-4.58%
EPS Next 2Y3.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%
Revenue Next Year0.34%
Revenue Next 2Y1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.19%
EBIT growth 3Y1.9%
EBIT growth 5Y1.25%
EBIT Next Year18.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.27%
FCF growth 3Y3.28%
FCF growth 5Y12.47%
OCF growth 1Y32.24%
OCF growth 3Y1.22%
OCF growth 5Y6.28%

TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ

What is the fundamental rating for TEVA stock?

ChartMill assigns a fundamental rating of 4 / 10 to TEVA.


What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.


Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?

TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 7 / 10.


What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 11.6 and the Price/Book (PB) ratio is 5.03.


What is the earnings growth outlook for TEVA PHARMACEUTICAL-SP ADR?

The Earnings per Share (EPS) of TEVA PHARMACEUTICAL-SP ADR (TEVA) is expected to decline by -4.58% in the next year.